Breaking Finance News

Hikma Pharmaceuticals PLC (LON:HIK) price target maintained at 2,550.00GBX, reported earlier today by JP Morgan Cazenove

Boasting a price of 0.00GBX, Hikma Pharmaceuticals PLC (LON:HIK) traded 0.80% lower on the day. The last stock close is down 4.75% relative to the two hundred day average, compared to the S&P 500 which has decreased -0.01% over the same time period. HIK has recorded a 50-day moving average of 2,273.76GBX and 200-day moving average of 2,221.42GBX. 508,620 shares of HIK traded hands, down from ann avg. trading volume of 581,547

JP Morgan Cazenove held the estimated target of Hikma Pharmaceuticals PLC (LON:HIK) at 2,550GBX, stating a possible upside of 0.00%,

Previously on 8/12/2016, Morgan Stanley released a statement about Hikma Pharmaceuticals PLC(LON:HIK) lowered the target price from 2,700.00GBX to 2,500.00GBX that suggested an upside of 0.00%.

Recent Performance Graph:

Hikma Pharmaceuticals PLC (LON:HIK)

A total of 9 firms have reported on the company. Four analysts rate the company a strong buy, six firms rate the company a buy, 0 firms rate the company a hold, 0 rate the company to underperform, and lastly 0 analystsrate the company as sell with a consensus target price of 32.71GBX

Hikma Pharmaceuticals PLC has a P/E of 26 with a one-year low of 1,575.00GBX and a 52 week high of 2,703.00GBX. The company’s total market value is currently 0.0 GBX.

General Information About Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company’s segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1, 120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business’ products include Argatroban, Fentanyl, Glycopyrrolate, and Nicardipine and Phenylephrine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.